Use of Human Plasma Depletion Technology and Antibody Arrays for the Rapid Detection of Biomarkers in Human Serum Samples
Richard Pembrey, Functional Proteomics Segment Manager, Sigma Aldrich
Date Posted: Thursday, January 10, 2008
To purchase a DVD containing all of the presentations featured at European Biomarkers Summit 2007 please go to the Select Biosciences website.
Launch presentation
About the speaker
Richard Pembrey
Functional Proteomics Segment Manager, Sigma Aldrich
Dr. Pembrey is currently a Strategic Marketing Segment Manager for Functional Proteomics at Sigma Aldrich Corporation. Involved in product management and high profile collaborative ventures worldwide since 1999, he has intimate knowledge of the development of key products for high-throughput research and discovery. Having managed portfolios including oligonucleotides, RNAi, recombinant protein expression and proteomic arrays, he offers perspective on the customer-driven development of platform technologies at Sigma to enable and accelerate life sciences research.
Abstract
There is growing demand for non-invasive methods that allow rapid detection and monitoring of biomarkers for carcinogenic disease states. Obtaining diseased tissue samples from patients generally presents complications. Associated secretory or tissue leakage proteins hold promise as potential biomarkers, however, the low occurrence of these proteins in plasma and the detection limits of available technologies has hindered effective high-throughput screening to date. In this study, antibody microarrays were used successfully for the rapid identification of protein expression changes in human plasma samples. Depletion technology was employed to remove 20 most abundant serum plasma proteins. This enabled identification of lower abundance tissue leakage proteins, as compared to non-depleted serum samples. Antibody arrays also produced differential protein expression profiles characteristic to either normal or diseased sera. Proteins were identified which displayed significantly different expression levels between the samples. Results from the arrays were validated with immunoblot and ELISA analyses. This study demonstrated that antibody arrays, used in conjunction with depletion technology, are a powerful tool for rapid expression profiling of hundreds of protein targets in serum plasma.
Launch presentation
Launch Presentation